valsartan has been researched along with Coronavirus Infections in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acanfora, C; Acanfora, D; Casucci, G; Ciccone, MM; Scicchitano, P | 2 |
| Javor, S; Salsano, A | 1 |
| Aarts, GWA; Bresser, P; Cornel, JH; Cortenbach, K; de Jager, CPC; de Leeuw, PW; Gommans, DHF; Hassing, RJ; Konijnenberg, LSF; Konst, RE; Koop, Y; Mensink, F; Mol, JQ; Nas, J; Pinto, YM; Pinto-Sietsma, SJ; Rooijakkers, MJP; Thannhauser, J; Tijssen, JGP; van Agtmael, MA; van den Heuvel, MM; van der Hoeven, HG; van Gilst, WH; van Kimmenade, RRJ; van Royen, N; van Rumund, A; Vart, P; Verbon, A; Verhaert, DVM; Vonk-Noordergraaf, A; Vos, JL | 1 |
| Bartoletti, M; Viale, P | 1 |
| Banerji, S; Mehrpour, O; Nakhaee, S; Shirazi, FM | 1 |
| Ambrosy, AP; Braunwald, E; Desvigne-Nickens, P; DeVore, AD; Gilotra, NA; Givertz, MM; Gorodeski, EZ; Greene, SJ; Gupta, D; Hernandez, AF; Lala, A; Lewis, GD; Mahr, C; Mann, DL; McNulty, SE; Mohammed, SF; Redfield, MM; Shah, P; Starling, RC; Vader, JM | 1 |
| Danzi, GB; De Maria, R; Di Tano, G; Loffi, M; Verde, S | 1 |
| Barbato, E; Bellis, A; Mauro, C; Morisco, C; Trimarco, B | 1 |
1 review(s) available for valsartan and Coronavirus Infections
| Article | Year |
|---|---|
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Neprilysin; Pandemics; Pneumonia, Viral; Tetrazoles; Valsartan | 2020 |
2 trial(s) available for valsartan and Coronavirus Infections
| Article | Year |
|---|---|
Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Betacoronavirus; Coronary Care Units; Coronavirus Infections; COVID-19; Double-Blind Method; Drug Administration Schedule; Humans; Inpatients; Multicenter Studies as Topic; Netherlands; Pandemics; Placebos; Pneumonia, Viral; Randomized Controlled Trials as Topic; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2; Time Factors; Valsartan | 2020 |
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Betacoronavirus; Biphenyl Compounds; Cardiotonic Agents; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Early Termination of Clinical Trials; Glomerular Filtration Rate; Heart Failure; Heart Transplantation; Heart-Assist Devices; Hospitalization; Humans; Hypotension; Natriuretic Peptide, Brain; Pandemics; Peptide Fragments; Pneumonia, Viral; SARS-CoV-2; Stroke Volume; Tetrazoles; Valsartan | 2020 |
6 other study(ies) available for valsartan and Coronavirus Infections
| Article | Year |
|---|---|
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apolipoproteins; Betacoronavirus; Biphenyl Compounds; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Inflammation; Mice; Neprilysin; Pandemics; Plaque, Atherosclerotic; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Tetrazoles; Valsartan | 2020 |
Why not consider an endothelin receptor antagonist against SARS-CoV-2?
Topics: Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Bosentan; Cells, Cultured; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Evaluation, Preclinical; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Models, Biological; Pandemics; Pneumonia, Viral; Receptor, Endothelin A; RNA, Viral; SARS-CoV-2; Valsartan; Virus Diseases | 2020 |
Sacubitril/valsartan in COVID-19 patients: the need for trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Betacoronavirus; Biphenyl Compounds; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Neprilysin; Pandemics; Pneumonia, Viral; SARS-CoV-2; Tetrazoles; Valsartan | 2020 |
Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
Topics: Aged; Anti-Inflammatory Agents; Anticoagulants; Antihypertensive Agents; Azithromycin; Combined Modality Therapy; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Enoxaparin; Humans; Hydroxychloroquine; Hypertension; Male; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Thrombophilia; Tomography, X-Ray Computed; Valsartan | 2020 |
Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Host-Pathogen Interactions; Humans; Losartan; Pandemics; Pneumonia, Viral; Prognosis; SARS-CoV-2; Severity of Illness Index; Telmisartan; Tomography, X-Ray Computed; Valsartan | 2020 |
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions].
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Biphenyl Compounds; Chronic Disease; Continuity of Patient Care; Coronavirus Infections; COVID-19; Delivery of Health Care; Disease Progression; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Pandemics; Pneumonia, Viral; Quarantine; Recurrence; SARS-CoV-2; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Telephone; Tetrazoles; Valsartan; Withholding Treatment | 2020 |